Neurokinin mediation of edema and inflammation

被引:78
作者
Campos, MM [1 ]
Calixto, JB [1 ]
机构
[1] Univ Fed Santa Catarina, Dept Pharmacol, Ctr Biol Sci, BR-88015420 Florianopolis, SC, Brazil
关键词
D O I
10.1054/npep.2000.0823
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this article is to furnish a brief review of the role played by neurokinins in the inflammatory process. Further attention is given to the mechanisms, as well as to the receptor subtypes involved in neurokinin-mediated inflammation, in an attempt to clarify the participation of neurokinins in different models of acute and chronic inflammation. The involvement of SP, NKA and NKB is also examined in relation to the major signs of inflammation, including edema formation, protein plasma extravasation and vasodilatation. Finally, we provide a general overview on the potential clinical applications of neurokinin antagonists, along with the involvement of neurokinins in human diseases. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 91 条
  • [1] CHARACTERIZATION OF THE CAPSAICIN-SENSITIVE COMPONENT OF CYCLOPHOSPHAMIDE-INDUCED INFLAMMATION IN THE RAT URINARY-BLADDER
    AHLUWALIA, A
    MAGGI, CA
    SANTICIOLI, P
    LECCI, A
    GIULIANI, S
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (04) : 1017 - 1022
  • [2] Impaired IL-1β-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice
    Ahluwalia, AA
    De Felipe, C
    O'Brien, J
    Hunt, SP
    Perretti, M
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (06) : 1013 - 1015
  • [3] INCREASED LEVELS OF SUBSTANCE-P AND CALCITONIN-GENE-RELATED PEPTIDE IN RAT ADJUVANT ARTHRITIS - A COMBINED IMMUNOHISTOCHEMICAL AND RADIOIMMUNOASSAY ANALYSIS
    AHMED, M
    BJURHOLM, A
    SCHULTZBERG, M
    THEODORSSON, E
    KREICBERGS, A
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (05): : 699 - 709
  • [4] Receptor subtypes involved in tachykinin-mediated edema formation
    Alves, RV
    Campos, MM
    Santos, ARS
    Calixto, JB
    [J]. PEPTIDES, 1999, 20 (08) : 921 - 927
  • [5] BATHIA M, 1998, P NATL ACAD SCI USA, V95, P4760
  • [6] BAYLISS WM, 1901, J PHYSL, V94, P173
  • [7] BENHATH J, 1995, EUR J PHARMACOL, V293, P87
  • [8] BERTRAND C, 1993, J IMMUNOL, V151, P4902
  • [9] BERTRAND C, 1993, J IMMUNOL, V150, P1479
  • [10] Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/0165-6147(96)10027-4